ATW grants new option shares
Momentum Public Relations
Press Release: February 5, 2018
ATW Tech (“AtmanCo” or the “Company”) (TSX-V:ATW) announces that a total of 2 387 000 share purchase options have been granted to officers, employees and consultants of the Company as well as members of the board of directors, pursuant to the terms of its share option plan (the “Plan”). These options are exercisable at $0.13 per share and expire on February 4, 2023. The Plan provides that options may be exercised on a cumulative basis over a period of four years from the date they are granted, as to one-fourth every year.
Additional information regarding the Company is available on SEDAR www.sedar.com. The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
ABOUT ATW TECH
ATW Tech (‘AtmanCo’) (TSX-V:ATW) is a leader in information technology, owner of several web platforms including VoxTel, Québec Rencontres, VuduMobile, Atman and Bloomed. VoxTel offers various interactive communication and landline and mobile carrier billing phone solutions. Quebec Rencontres is a web and mobile social network application catered to building serious and sustainable relationships. VuduMobile is specialized the text messaging business for enterprises through its unique, user-friendly and bilingual test messaging application et turnkey solution allowing management of text message management programs in all kind of businesses. Atman and its APIs enable companies to optimize their human capital. Bloomed is a cloud-based platform to manage data (smart data) on consumers and their behaviors, which is developed for marketing agencies and their campaigns for the consumer and corporate markets.
SOURCE:
ATW TECH (AtmanCo) Michel Guay Founder, president and CEO Tel.: 514.935.5959 ext. 301 mguay@atwtech.com www.atwtech.com |
Simon Bédard, CA, CPA, CFA, MBA CFO Tel. : 514.935.5959 ext. 304 sbedard@atmanco.com |
Relevium Improves Financial Position and Provides Updates on Warrants Exercises and Share for Services Agreement
Momentum Public Relations
Press Release: February 5, 2018
Relevium Technologies Inc. (TSX VENTURE:RLV)(FRANKFURT:6BX) (the “Company” or “Relevium”) is pleased to report improvements on its financial position, provide an update on warrants exercised to date and on shares issued to its corporate secretary on a share for services agreement.
Improved Financial Position and Warrants Exercises to-date
The company has received warrant and options exercises and issued 13,591,361 shares at a weighted average price of $0.15, resulting in total cash proceeds of $2,008,704. Aurelio Useche, CEO stated: “Combined with the debt conversion announced on December 12, 2017, the company has significantly improved its financial position. We want to thank our loyal shareholders for their support and loyalty as we pursue our objectives in 2018.”
Shares Issued to Corporate Secretary per Share for Services Agreement
The company also announced it has issued 27,300 shares on Friday February 2, 2018 at a deemed price of $0.183146 per share to the Company’s Corporate Secretary, Mr. David A. Johnson, pursuant to a shares-for-services agreement disclosed in a company press release dated October 20, 2017. The shares are subject to a four month hold period. Pricing was determined using the VWAP on the close of February 2, 2018.
About Relevium Technologies
Relevium is a TSXV-listed company focused on growth through the acquisition of businesses, products and/or technologies with a focus on e-commerce in the growing health and wellness sector. Relevium Technologies Inc. also holds patented intellectual property for the use of static magnetic fields for application on wearable devices.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as “intends” or “anticipates”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “should”, “would” or “occur”. Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will obtain stock exchange approval of the Offering, the proposed acquisition will occur as anticipated, that the Company will raise sufficient funds, and that the Company will obtain all requisite approvals of the acquisition. These forward- looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed acquisitions may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds under the Offering. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
Aurelio Useche, President and CEO
Relevium Technologies Inc.
Edward Ierfino
Investor Relations
+1(514) 562-1374
eierfino@releviumcorp.com
www.releviumtechnologies.com
- Published in Relevium Technologies
Tetra Bio-Pharma Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug
Momentum Public Relations
Press Release: February 5, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company’s PPP001 prescription smokable dried cannabis product.
Coinciding with World Cancer Day 2018, Tetra is now ready to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients, the first registration trial in the world for smokable cannabinoid-based drug. This trial is expected to be a landmark study, enrolling a total of 946 subjects, evaluating the therapeutic benefits of a cannabinoid prescription drug in improving quality of life and treating pain in terminal cancer patients.
“This is an especially significant and noteworthy milestone for the lead candidate in our product pipeline,” said Bernard Fortier, Tetra’s CEO, “as it positions Tetra to potentially be the first company with a Health Canada approved, cannabinoid-based drug on the market aimed at treating breakthrough pain in cancer patients. The advanced cancer pain market is a $2.4B market1; this is a significant and important opportunity for the Company as our drug PPP001 has the potential to help reduce the reliance on opioids for the management of severe pain.”
The first and main recruitment center of the trial will be in Montreal at Santé Cannabis, Québec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.
The PPP001 Phase 3 trial will evaluate the effects of Tetra’s smokable cannabinoid-based drug made from natural dried cannabis. Tetra previously entered into a supply agreement with Aphria Inc., to use Aphria’s unique blend of dried medical cannabis in its PPP001 clinical trial. Aphria owns an 8.5% stake in Tetra.
As part of the clinical trial, Tetra will also collect the pharmaco-economics evidence required from insurers in order to support the reimbursement of the first cannabis prescription drug. “Today, most private insurance plans do not cover cannabis treatment, nor is public reimbursement available, making this therapeutic option costly for patients. It is very important for us to bring a new therapeutic option for patients in the form of an approved prescription drug and to take action in order to have it reimbursed for patients” commented Bernard Fortier, CEO.
The trial aims to demonstrate that PPP001 eases suffering and facilitates a more serene experience of living and dying in terminal cancer patients. If conclusive, Tetra will submit a filing for a Drug Identification Number (DIN) to Health Canada in 2019, thus providing a new noninvasive treatment to relieve pain for cancer patient. With this approval, Tetra expects to be on time with its previously announced schedule with the development of PPP001, culminating in a potential launch in Canada by Q1, 2020 and in the US by Q3, 2020.
Dr Guy Chamberland, Tetra’s Chief Scientific Officer (CSO) explained that: “The development of PPP001 for patients with advanced cancer is an important commitment for Tetra, given that cancer patients suffer from severe pain which is often accompanied by depression and insomnia. Medical cannabis has been shown to help patients beyond the immediate benefit of pain relief.”
“With the expertise of Santé Cannabis, we expect to demonstrate the clinical benefits of PPP001 on the quality of life of advanced cancer patients. It’s important to note that our clinical program will also address the potential of PPP001 to reduce the reliance on opioids for management of severe pain. We expect that, once it is approved as a drug under prescription, PPP001 will be included over time ahead of opioids treatment for those patients with terminal cancer pain. The Company will continue to maintain a transparent and direct line of communication with Health Canada and the U.S. FDA to ensure that we address the issues required for drug approval. PPP001 is about patients first, ” added Dr. Guy Chamberland.
Tetra worked with Santé Cannabis physicians to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer patients and have focused the clinical development on a first indication in patients with advanced cancer. The Phase III clinical trial will be performed by the medical team of Santé Cannabis.
“Throughout my clinical experience assessing and following more than 600 medical cannabis patients, cannabis inhalation remains a critical option to provide rapid relief from a wide variety of symptoms associated with advanced cancer, ” said Dr. Antonio Vigano, Principal Investigator of the trial and Research Director of Santé Cannabis. “We will rigorously assess the safety, efficacy and tolerability of PPP001 to support the population of cancer patients by bringing an important therapeutic tool to the same standard of prescription drugs It is great to be celebrating World Cancer Day 2018 with the first large scale clinical study to prove that medical cannabis can ease the suffering and improve quality of life of many cancer patients, particularly when they most need it.”
About Cancer Pain:
In the USA, 1,5 million patients suffer from cancer pain2. Pain is one of the most frightening of all cancer symptoms for patients and their families3. According to statistics published by the American Cancer Society in 20024, 50% to 70% of people with cancer experience some degree of pain, with a quarter of them actually dying in pain. Without adequate relief of their pain, their quality of life is negatively impacted. Furthermore, the incidence of pain in advanced stages of invasive cancer approaches 80% and it is 90% in patients with bone metastases5.
- https://decisionresourcesgroup.com/report/141466-biopharma-cancer-pain-2015
- Melnikova I. Pain market 2010 ;, doi:10.1038/nrd3226
- Winslow M, Seymour J, Clark D. 2005. Stories of cancer pain: a historical perspective. J Pain Symptom Manage, 29:22-31.
- American Cancer Society. 2002. Cancer facts and figures 2002
- Pharo GH, Zhou L. 2005. Pharmacologic Management of Cancer Pain. JAOA, 105:S21-28.
About PPP001:
PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9,5% THC and 2,5% CBD.
About Aphria:
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
anne-sophie.courtois@tetrabiopharma.com
(514) 360-8040 Ext. 210
For media information, please contact:
Daniel Granger
Daniel.granger@acjcommunication.com
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556
- Published in Marijuana, Medical Marijuana, Tetra Bio Pharma
Crystal Lake shareholders approve all matters at AGM
Momentum Public Relations
Press Release: February 1, 2018
Crystal Lake Mining Corp. has released the results of its annual general meeting of shareholders which was held on Jan. 31, 2018.
Richard Savage, John Meekison, Alphonse Ruggiero and Wally Boguski were re-elected to the board. All motions were approved by shareholders and the company’s shareholder rights plan was renewed. Mr. Savage will continue as chief executive officer and Mr. Ruggiero will continue as chief financial officer.
The company thanks shareholders for their continued support and look forward to an exciting year ahead.
About the company
Crystal Lake is a mineral exploration/development company with a focus on creating value through the exploration and development of the company’s Ontario mineral properties.
We seek Safe Harbor.
- Published in Crystal Lake Mining
Crystal Lake enters new deal for L1, L5 properties
Momentum Public Relations
News Release: January 30, 2018
Crystal Lake Mining Corp.(CLM:V) has entered into an agreement with Emerald Lake Development Corp. (ELD), which will create a more favourable path to 100-per-cent ownership of the L1 and L5 properties, both in the Chapple township, district of Rainy River. The L1/L5 agreement, which will supersede and replace all prior agreements concerning these properties, will allow the company to acquire a 100-per-cent interest in the properties on the terms fully disclosed in its most recent management’s discussion and analysis at Sept. 30, 2017. This may be viewed by visiting SEDAR.
The company’s new website is currently under construction and is expected to be operational shortly with up-to-date corporate and geological information.
About Crystal Lake Mining Corp.
Crystal Lake Mining is a mineral exploration/development company focused on creating value through the exploration and development of its Ontario and B.C. mineral properties.
- Published in Crystal Lake Mining, Mining
Tetra Bio-Pharma Receives Health Canada Approval for Phase 2 Cannabis Oil Trial in Partnership with Sante Cannabis
Momentum Public Relations
Press Release: January 29, 2018
Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce the approval by Health Canada of a Phase 2 clinical trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil (THC & CBD) to improve uncontrolled chronic pain in cancer and non-cancer patients.
“To our knowledge, this is the first Health Canada-approved phase 2, randomized, double-blind, placebo-controlled clinical trial using encapsulated medical cannabis oil in Canada,” said Bernard Fortier, Tetra Bio-Pharma’s CEO. According to an Eight Capital analysis1, the cannabis oil market is expected to reach 1.5B$ in 2024.
“This is a significant milestone in our mission to become a global bio-pharmaceutical leader in cannabinoids-based drug development. We currently have a strong pipeline of five cannabinoid-based products, all launched last year and using different delivery systems, in various stages towards Health Canada and FDA approval.”
The Phase 2 trial will be conducted with Montreal-based Santé Cannabis, Quebec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.
According to Health Canada data2, the annual Canadian cannabis oil production for medical purposes was 22,766 kg between October 1st 2016 and September 30th 2017, and is growing continuously. In the third quarter of 2017, it grew 24% from Q2 (Apr-Jun) to Q3 (Jul-Sep)1.
Dr. Guy Chamberland, Tetra’s Chief Scientific Officer (CSO), also commented that “there is limited scientific and clinical information on the different doses and ratios of medical cannabis oil in the management of pain. This type of clinical trial is required to generate the urgently needed safety and efficacy data required by physicians and pharmacists for the adequate care of patients”.
“We are excited to launch this trial to build the evidence base for medical cannabis in chronic pain, and to demonstrate the leadership of Santé Cannabis on the world stage” said Dr. Antonio Vigano, Research Director of Santé Cannabis and McGill University Associate Professor of Oncology. “At Santé Cannabis, our team observes the impact that cannabis oil has for our patients. For many, medical cannabis can reduce or even eliminate the need for other pharmacological medications. As clinicians and researchers, we must pursue these critical steps to quantify its benefits and to investigate potential risks.”
These studies are part of the Company’s sales and marketing strategy required to effectively penetrate a physician-pharmacist market. The outcome of these studies will also support Tetra’s overall drug development strategy and it is expected that this will allow Tetra to reduce the overall time-to-market for a number of its cannabinoids-based prescription drugs. The company will also use this data to create novel new products that will allow Tetra to further increase its share in the cannabis oil market.
Last year, Tetra launched a number of drug development programs that are expected to lead to the commercialization of cannabinoid-based prescription drugs, making it one of the world leaders in cannabinoid pharmaceuticals. Tetra’s vision is to develop an evidence-based approach similar to that of any other prescription drug, thereby allowing physicians to prescribe, and pharmacists to dispense, these medicines to patients in need.
After receiving approval of a phase 1 clinical trial for its PPP005 cannabis oil program in mid-January of this year, Tetra is now launching a phase 2 trial to assess if cannabis oil treatment will reduce the amount of concurrent pain medications and the need for rescue medications to control chronic cancer and non-cancer pain. This phase 2 clinical trial is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of different doses and ratios of medical cannabis oil. In addition, the study will evaluate the effects on improving symptom burden and on cognition and mood in those chronic pain patients.
Tetra and Santé Cannabis have been preparing for several months to initiate this clinical program. The team at Santé Cannabis has grown to include qualified and experienced personnel in the conduct of clinical trials in compliance with Good Clinical Practices. This trial is driven by the medical experts of Santé Cannabis and will provide much needed safety and efficacy data in this patient population, as well as provide Tetra with critical knowledge of the benefits of different ratios of THC and CBD in pain management.
1: Cannabis Sector, Eight Capital Estimates, July 2017
2: Health Canada Market Data, [https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-use-marijuana/licensed-producers/market-data.html]
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.
More information at: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(514) 360-8040 Ext. 210
anne-sophie.courtois@tetrabiopharma.com
- Published in Marijuana, Medical Marijuana, Tetra Bio Pharma
Albert Mining Inc. Announces Results of Chapais Drill Program in Quebec
Momentum Public Relations
Press Release: January 24
Albert Mining Inc. (the “Company” or “Albert”) (TSX-V: AIIM), a mining exploration company and a leader in the use of Artificial Intelligence (AI) and advanced knowledge-extraction techniques in the mining sector, and Everton Resources Inc. (TSX-V: EVR) are pleased to announce results from their recent drilling campaign on the Chapais property which is situated immediately west of the Springer Copper Mine at Chapais, Quebec.
The drilling tested copper targets generated by Albert Mining’s proprietary CARDS 2D (Computer Aided Resources Detection System) system: The first hole (CHA-17-10) investigated Target A located at the hinge of a large fold which mimics the structural context at the nearby (3 km) Springer Mine. The two other holes (CHA-17-11 and CHA-17-12) were positioned on Target C located two kilometers to the northwest (Table 1). The core was logged by visual description and spot-checked for multi-elements by portable XRF. Selected core segments 0.5 to 1 meter in length were split and submitted to ALS Minerals for gold determination by Fire-Assay with AA finish, and for other elements by ICP-MS after partial digestion by aqua regia.
Table 1. Drill hole data.
Hole | Longitude | Latitude | Azm | Dip | Length |
id | (WGS 1984) | (?) | (?) | (m) | |
CHA-17-10 | 74? 52′ 40” W | 49? 48′ 05” N | 178 | -50 | 197 |
CHA-17-11 | 74? 54′ 07” W | 49? 48′ 40” N | 170 | -50 | 237 |
CHA-17-12 | 74? 54′ 07” W | 49? 48′ 40” N | 340 | -50 | 237 |
total | 671 |
The first hole intersected two one meter-thick (along core axis) mineralized zones assaying 1.61% Zn; and 1.74% Zn, and 0.59% Cu, respectively from 158.4 m to 159.4 m and 190.3 m to 191.3 m. These Zn – Cu values are associated with sulfidic and graphitic horizons in intensely folded fine-grained sediments of the Blondeau Fm. which locally shows a high zinc background (1000 – 2000 ppm). The first hole returned slightly anomalous gold values of 0.142 g/t Au over 1 m and 0.128 g/t Au over 0.5 m (along core axis), associated with semi massive sulfides. In the two last holes, pyroxenitewas observed to alternate with metasediments and volcanic flows of ultramafic affinities.
In addition to base metals, the Chapais property offers a strong potential for gold as exemplified by an historical reverse circulation drill hole that returned 6.29 g/t Au from a till sample (GM46158).
The scientific and technical content of this release was approved by Remi Charbonneau, P.Geo., a qualified person as defined by the National Instrument 43-101.
To quote Mr. Michel Fontaine, President & CEO of Albert Mining; “The encouraging results obtained from the short drilling campaign on the Chapais property will be followed by detailed IP geophysic surveying and additional till sampling”.
About Albert Mining Inc.
Albert is a junior mining exploration company with an extensive portfolio of gold, copper and diamond properties in Quebec. Albert also recently acquired all assets from DIAGNOS Inc.’s mining division, including the Computer Aided Resources Detection System (“CARDS”). Albert can count on a multidisciplinary team that includes professionals in geophysics, geology, Artificial Intelligence, and mathematics. The Company’s objective is to develop a new royalty stream by significantly enhancing and participating in the exploration success rate of mining.
For further information, please contact:
Michel Fontaine
President and CEO of Albert Mining Inc.
Telephone: 514-994-5843
Fax: 613-422-0773
Email: michel@albertmining.com
Website: www.albertmining.com
- Published in Albert Mining, Artificial Intelligence, Mining, Technology
Blue Moon Quoted on Pink Sheets and DTC Eligible; Positive Impact From US Corporate Tax Rate Reduction
Momentum Public Relations
Press Release: January 23
Blue Moon Zinc Corp. (TSXV: MOON; US OTC: BMOOF) (the “Company“) is pleased to report that the common shares of the Company are now quoted for trading in the United States on the OTC Pink Sheets under the trading symbol BMOOF. In addition, the Company’s common shares are eligible for delivery and depository services of The Depository Trust Company (the “DTC”) to facilitate electronic settlement of transfers of its common shares in the United States. Securities that are eligible to be electronically cleared and settled through the DTC are considered “DTC eligible.” This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and greatly reduces transactional costs for participating stock brokerages. Investors can find the current Canadian financial disclosure of the Company on www.sedar.com.
Effective January 1, 2018, corporate tax rates in the United States were reduced from 35% to 21%, among other changes favoring US businesses. The Company’s Blue Moon zinc deposit is domiciled in the US and the corporate tax reduction is expected to be beneficial to the project and the Company’s Preliminary Economic Assessment (“PEA”) expected to be released in late Q1 2018.
Patrick McGrath, Chief Executive officer, stated, “The US quotation with DTC eligibility should enhance and simplify trading of our shares in the US. The Company’s Blue Moon Zinc deposit is based in the US and we believe being quoted and tradable in the US is complementary. We also welcome the recent US corporate tax reduction to 21% which we believe will improve the economics in the upcoming PEA”
About Blue Moon
The 100% owned Blue Moon polymetallic deposit has a Mineral Resource estimate of 3.7 million indicated tons with a grade of 8.3% zinc equivalence including approximately 377 million pounds of zinc and 4.1 million inferred tons with a grade of 7.8% zinc equivalence including approximately 395 million pounds of zinc with significant credits of copper, silver and gold. The resource is open at depth and along strike and historical metallurgical testing indicates excellent recovery and a clean zinc concentrate. A NI 43-101 report detailing the resource and summarizing metallurgical recoveries is available on the company’s website (www.bluemoonmining.com) and filed on SEDAR on November 13, 2017. The Company plans to advance the Blue Moon project through to feasibility, permitting and ultimately production.
Qualified Persons
Jack McClintock, P. Eng, a Director of the Company, is a qualified person as defined by NI 43-101, has reviewed the scientific and technical information that forms the basis for this press release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Resource estimates included in this news release are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions set forth in the relevant technical report and otherwise, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices for zinc, the results of future exploration, uncertainties related to the ability to obtain necessary permits, licenses and titles, changes in government policies regarding mining, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Readers are cautioned not to place undue reliance on this forward-looking information, which is given as of the date it is expressed in this press release, and the Company undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
The securities referenced in this news release have not and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.
SOURCE Blue Moon Zinc Corp.
View original content: http://www.newswire.ca/en/releases/archive/January2018/23/c2491.html
Contact:
Patrick McGrath, CEO, 1-832-499-6009, pmcgrath@bluemoonmining.com; For additional information related to communications, media relations and investor relations please contact: Terry Bramhall, 1-604-833-6999, tbramhall@bluemoonmining.com
MOBI724 Global Solutions Inc. (CSE: MOS) Signs a Commercial Agreement With Credicorp Bank to Implement Its Card-Linked Offers & Rewards Platform
Momentum Public Relations
Press Release: January 23, 2018
MOBI724 Global Solutions Inc. (“MOBI724” or the “Company”) (CSE:MOS), (OTCQB:MOBIF), a FinTech leader offering integrated EMV payment, Card-Linked Offers, Digital Marketing and Business Intelligence Solutions, entered into an commercial agreement with Credicorp Bank S.A. (“CrediCorp Bank”), a leading Panamanian Bank, to provide MOBI724’s suite of integrated Loyalty Solutions, including Card-Linked Offers & Rewards, Digital Marketing and Business Intelligence Solutions, through the Visa Loyalty and Offers Platform.
MOBI724’s Card-Linked Offers & Rewards platform will allow members of Credicorp Bank’s Benefits and Loyalty Programme the possibility to redeem their points directly at the Point of Sale of participating retailers, using their credit cards in a single transaction and in a seamless customer experience, as well as the immediate redemption of discounts and coupons at the Point of Sale when using their credit card; leveraging MOBI724’s integration and connectivity with the Visa Offers Platform.
Marcel Vienneau, CEO of MOBI724, stated “We are very excited about the opportunity to launch our platform with our first client in Panama. By leveraging MOBI724’s integration and connectivity to the Visa Offers Platform, we are able to provide Credicorp Bank with our innovative Card-Linked Offers and Rewards Platform. This, in turn, will allow Credicorp Bank to maximize cardholders’ purchase activity and to generate incremental revenues for the bank”.
Raul Reyes, VP of Cards and Payment Systems for Credicorp Bank, stated “We strongly believe that through our alliance with MOBI724 Card-Linked Offers and Rewards Platform, we will be able to give our customers an innovative and seamless user experience for redeeming their rewards”.
About MOBI724 Global Solutions
“We enable smart transactions anywhere”
MOBI724, a leader in the FinTech industry based in Montreal (Canada), offers a unique and fully integrated suite of payment, digital marketing and business intelligence solutions with a combined EMV Payment, Card Linked Offers, and Digital Marketing & Business Intelligence platform that works on any card and any mobile device. MOBI724’s solutions add value to all types of transactions benefiting banks, retailers and cardholders by leveraging available user and purchasing data to increase transaction volumes and spend. MOBI724 provides a turnkey solution to its clients to capture card transactions on any mobile device, at any point of sale or from any payment card. MOBI724 provides its customers with full and comprehensive traceability and enriched consumer data through its offering. Its solutions enable card associations, retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver and “track and measure” incentive campaigns worldwide to any mobile device and allow its redemption at any point of sales.
About Credicorp Bank
Established in 1992, Credicorp Bank is a full-service Panamanian banking institution and one of the most important in the country. Credicorp Bank is part of CREDICORP FINANCIAL GROUP, which is composed of 7 subsidiaries in the areas of banking, insurance, investments, asset management and Hydroelectric ventures.
Cutting edge technologies has been their hallmark and throughout the past two decades have been constantly innovating, striving to offer customized products and services to meet the financial needs of their clients.
Their strong performance in recent years earned them the BEST COMMERCIAL BANK IN PANAMA 2012 award, granted by the prestigious WORLD FINANCE magazine.
Legal Disclaimer
Certain statements in this document, including those which express management’s expectations or estimations with regard to the Company’s future performance, constitute “forward-looking statements” as understood by applicable securities laws. Forward-looking statements are, of necessity, based on a certain number of estimates and hypotheses; while management considers these to be accurate at the time they are expressed, they are inherently subject to significant uncertainties and risks on the commercial, economic and competitive levels. We advise readers that these forward-looking statements are subject to risks, uncertainties, and other known and unknown factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied in these forward-looking statements. Investors are advised to not rely unduly on the forward-looking statements. This advisory applies to all forward-looking statements, whether expressed orally or in writing, attributed to the Company or to any individual expressing them in the name of the Company. Unless required by law, the Company is under no obligation to publicly update these forward-looking statements, whether to reflect new information, future events, or other circumstances.
The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy. This news release does not constitute a solicitation to buy or sell any securities in the United States.
For further information, please visit MOBI724.com or contact:
Investor Relations:
Mr. Andreas Curkovic
Proconsul Capital Ltd.
T: 416-577-9927;
E: andreascurkovic@sympatico.ca
- Published in Mobi724 Global Solutions, Technology
ATW Tech Completes a Private Placement of Units of $423,640
Momentum Public Relations
Press Release: December 22, 2017
AtmanCo inc. (“AtmanCo” or the “Company”) (TSX-V:ATW) is pleased to announce the closing of a private placement consisting of the issuance of 3 530 333 units at a price of $0.12 per unit, for total gross proceeds of $423,640. Each unit consists of one common share and one common share purchase warrant giving the holder the right to subscribe for one common share at a price of $0.15 from a period of 3 years.
The securities issued under this private placement are subject to a four-month hold period. This private placement remains subject to the approval of the TSX Venture Exchange. A commission of $840 is paid to a broker.
Additional information regarding the Company is available on SEDAR www.sedar.com. The TSX Venture Exchange and its Regulatory Services provider (as per meaning assigned to this term in TSX Venture Exchange’s policies) bear no liability as to the relevance or accuracy of this press release.
ABOUT ATW TECH
ATW Tech (‘AtmanCo’) (TSX-V:ATW) is a leader in information technology, owner of several web platforms including VoxTel, Québec Rencontres, VuduMobile, Atman and Bloomed. VoxTel offers various interactive landline and mobile carrier billing phone solutions. Quebec Rencontres is a web and mobile social network application catered to building serious and sustainable relationships. VuduMobile is specialized the text messaging business for enterprises through its unique, user-friendly and bilingual test messaging application et turnkey solution allowing management of text message management programs in all kind of businesses. Atman and its APIs enable companies to optimize their human capital. Bloomed is a cloud-based platform to manage data (smart data) on consumers and their behaviors, which is developed for marketing agencies and their campaigns for the consumer and corporate markets.
SOURCE:
ATW TECH (AtmanCo) | ||
Michel Guay | Simon Bédard, CA, CPA, CFA, MBA | |
Founder, president and CEO | CFO | |
Tel.: 514.935.5959 ext. 301 | Tel. : 514.935.5959 ext. 304 | |
mguay@atmanco.com | sbedard@atmanco.com | |
www.atwtech.com |
- Published in Atmanco